329 related articles for article (PubMed ID: 32538186)
1. Shedding light on developmental drugs for idiopathic pulmonary fibrosis.
Spagnolo P; Bonella F; Ryerson CJ; Tzouvelekis A; Maher TM
Expert Opin Investig Drugs; 2020 Aug; 29(8):797-808. PubMed ID: 32538186
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targets in idiopathic pulmonary fibrosis.
Kolb M; Bonella F; Wollin L
Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
[TBL] [Abstract][Full Text] [Related]
3. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.
Aryal S; Nathan SD
Expert Opin Emerg Drugs; 2018 Jun; 23(2):159-172. PubMed ID: 29718783
[TBL] [Abstract][Full Text] [Related]
4. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
George PM; Wells AU
Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
[TBL] [Abstract][Full Text] [Related]
5. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Wongkarnjana A; Yanagihara T; Kolb MR
Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
[No Abstract] [Full Text] [Related]
6. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.
Ahluwalia N; Shea BS; Tager AM
Am J Respir Crit Care Med; 2014 Oct; 190(8):867-78. PubMed ID: 25090037
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
9. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
Karimi-Shah BA; Chowdhury BA
N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
[No Abstract] [Full Text] [Related]
10. Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?
Inchingolo R; Condoluci C; Smargiassi A; Mastrobattista A; Boccabella C; Comes A; Golfi N; Richeldi L
Expert Opin Pharmacother; 2017 Oct; 18(15):1583-1594. PubMed ID: 28933616
[TBL] [Abstract][Full Text] [Related]
11. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
Maher TM; Molina-Molina M; Russell AM; Bonella F; Jouneau S; Ripamonti E; Axmann J; Vancheri C
BMC Pulm Med; 2017 Sep; 17(1):124. PubMed ID: 28915874
[TBL] [Abstract][Full Text] [Related]
12. Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
Singh V; Ulasov I; Gupta S; Singh A; Roy VK; Kharwar RK
Discov Med; 2024 Jan; 36(180):22-47. PubMed ID: 38273744
[TBL] [Abstract][Full Text] [Related]
13. An updated safety review of the drug treatments for idiopathic pulmonary fibrosis.
Sgalla G; Comes A; Richeldi L
Expert Opin Drug Saf; 2021 Sep; 20(9):1035-1048. PubMed ID: 33881959
[TBL] [Abstract][Full Text] [Related]
14. Pirfenidone treatment of idiopathic pulmonary fibrosis.
Azuma A
Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
16. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development.
Spagnolo P; Kropski JA; Jones MG; Lee JS; Rossi G; Karampitsakos T; Maher TM; Tzouvelekis A; Ryerson CJ
Pharmacol Ther; 2021 Jun; 222():107798. PubMed ID: 33359599
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials.
Sgalla G; Lerede M; Richeldi L
Expert Opin Emerg Drugs; 2021 Jun; 26(2):93-101. PubMed ID: 33998354
[TBL] [Abstract][Full Text] [Related]
20. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
